<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Johnson LA</submitter><funding>NIH-NIDDK</funding><funding>Michigan Gastrointestinal Peptide Research Center</funding><pagination>724-736</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5881735</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(6)</volume><pubmed_abstract>&lt;h4>Background and aims&lt;/h4>Intestinal fibrosis is a frequent complication in Crohn's disease [CD]. The mouse Salmonella typhimurium model, due to its simplicity, reproducibility, manipulability, and penetrance, is an established fibrosis model for drug discovery and preclinical trials. However, the severity of fibrosis and mortality are host- and bacterial strain-dependent, thus limiting the original model. We re-evaluated the S. typhimurium model to optimise fibrosis and survival, using commercially available mouse strains.&lt;h4>Methods&lt;/h4>Fibrotic and inflammatory markers were evaluated across S. typhimurium ΔaroA:C57bl/6 studies performed in our laboratory. A model optimisation study was performed using three commercially available mouse strains [CBA/J, DBA/J, and 129S1/SvImJ] infected </pubmed_abstract><journal>Journal of Crohn's &amp; colitis</journal><pubmed_title>Optimisation of Intestinal Fibrosis and Survival in the Mouse S. Typhimurium Model for Anti-fibrotic Drug Discovery and Preclinical Applications.</pubmed_title><pmcid>PMC5881735</pmcid><funding_grant_id>K08DK080172</funding_grant_id><funding_grant_id>5P30DK034933</funding_grant_id><pubmed_authors>Higgins PDR</pubmed_authors><pubmed_authors>Johnson LA</pubmed_authors><pubmed_authors>Neubig RR</pubmed_authors><pubmed_authors>Moons DS</pubmed_authors><pubmed_authors>Larsen SD</pubmed_authors><pubmed_authors>Rodansky ES</pubmed_authors></additional><is_claimable>false</is_claimable><name>Optimisation of Intestinal Fibrosis and Survival in the Mouse S. Typhimurium Model for Anti-fibrotic Drug Discovery and Preclinical Applications.</name><description>&lt;h4>Background and aims&lt;/h4>Intestinal fibrosis is a frequent complication in Crohn's disease [CD]. The mouse Salmonella typhimurium model, due to its simplicity, reproducibility, manipulability, and penetrance, is an established fibrosis model for drug discovery and preclinical trials. However, the severity of fibrosis and mortality are host- and bacterial strain-dependent, thus limiting the original model. We re-evaluated the S. typhimurium model to optimise fibrosis and survival, using commercially available mouse strains.&lt;h4>Methods&lt;/h4>Fibrotic and inflammatory markers were evaluated across S. typhimurium ΔaroA:C57bl/6 studies performed in our laboratory. A model optimisation study was performed using three commercially available mouse strains [CBA/J, DBA/J, and 129S1/SvImJ] infected </description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jun</publication><modification>2025-05-18T12:40:18.885Z</modification><creation>2025-05-18T12:40:18.885Z</creation></dates><accession>S-EPMC5881735</accession><cross_references><pubmed>27986839</pubmed><doi>10.1093/ecco-jcc/jjw210</doi></cross_references></HashMap>